Renal Cancer - Results from #940

A Contemporary Clinicopathologic Analysis of Patients With Renal Cell Carcinoma and Vena Cava Involvement. June 13, 2023

The Current Role of Lymph Node Dissection in Nonmetastatic Localized Renal Cell Carcinoma. June 12, 2023

Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab. June 12, 2023

Renal Cell Carcinoma of Variant Histology: Biology and Therapies. June 9, 2023

Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review. June 9, 2023

Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. June 8, 2023

Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy. June 8, 2023

Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma. June 7, 2023

A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. June 7, 2023

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial June 6, 2023

Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors. June 6, 2023

Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab. June 6, 2023

Excavation of diagnostic biomarkers and construction of prognostic model for clear cell renal cell carcinoma based on urine proteomics. June 5, 2023

Assessing the Trade-off Between the Safety and Effectiveness of Off-clamp Robotic Partial Nephrectomy for Renal Masses with a High RENAL Score: A Propensity Score-matched Comparison of Perioperative and Functional Outcomes in a Multicenter Analysis. June 5, 2023

State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma. June 2, 2023

First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma. June 2, 2023

The Role of the Pathologist in Renal Cell Carcinoma Management. June 2, 2023

Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease. June 2, 2023

Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System. June 1, 2023

A Review of the Recommendations and Strength of Evidence for Clinical Practice Guidelines on the Management of Small Renal Masses. June 1, 2023

Page 48 of 458